David Schlachet, Chairman of the Board
David Schlachet joined our Board of Directors during April 2014. Mr. Schlachet serves as a director of several public and private Israeli companies. Mr. Schlachet served as chairman of Syneron Medical Ltd., an Israeli aesthetic medical device company, from April 2013 to February 2014 and prior to that, he served as Syneron Medical’s Chief Executive Officer from November 2005 to May 2007, after serving as its Chief Financial Officer beginning in June 2004. From November 2008 to November 2012, Mr. Schlachet served as a director of the Tel Aviv Stock Exchange and Chairman of its Audit Committee. From 2000 to June 2004 Mr. Schlachet served as Managing Partner of Biocom, a venture capital fund specializing in the life sciences field. From 1995 to 2000, Mr. Schlachet served as a Senior Vice President and Chief Financial Officer of Strauss Elite Holdings, an Israeli packaged food group, and from 1997 to 2000 he also served as active Chairman of Elite Industries, an Israeli coffee, confectionary and salty snacks manufacturer. From 1988 till 1995 Mr. Schlachet served as Vice President of Finance and Administration of the Weizmann Institute of Science, Israel’s premier post-graduate scientific research institute, and as Chief Executive Officer of its technology transfer company Yeda Research and Development Company, Ltd. Mr. Schlachet serves as a director of Syneron Medical Ltd, EzChip Semiconductor Ltd, Taya Investments Ltd (Chairman), Mazor Robotics Ltd and BioCancell Ltd. Mr. Schlachet also serves as Chairman of the Board of our subsidiary Cell Cure Neurosciences Ltd. Mr. Schlachet holds a B.Sc. degree in chemical engineering and an M.B.A. from the Tel-Aviv University.
Michael D. West, Ph.D.
Michael D. West, Ph.D. became our Chief Executive Officer during October 2007, and has served on the Board of Directors since 2002. Prior to becoming our Chief Executive Officer, Dr. West served as Chief Executive Officer, President, and Chief Scientific Officer of Advanced Cell Technology, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Dr. West also founded Geron Corporation of Menlo Park, California, and from 1990 to 1998 he was a Director and Vice-President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.
Alfred D. Kingsley
Alfred D. Kingsley joined the Board of Directors and became Chairman of the Board during July 2009. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt Corp. served as our financial advisor from 1998 until June 30, 2009. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.
Robert W. Peabody
Robert W. Peabody is our Senior Vice-President, Chief Operating Officer, and Chief Financial Officer. Mr. Peabody has served as our Senior Vice-President and Chief Operating Officer since 2007, and also served on an interim basis as our Chief Financial Officer from September 2010 until October 2011 before reassuming the role in May 2013. Prior to joining BioTime in October 2007, Mr. Peabody served as a Vice-President of Advanced Cell Technology, Inc., and also served on their board of directors from 1998 to 2006. Prior to joining ACT, Mr. Peabody spent 14 years as a Regional Controller for Ecolab, Inc., a Fortune 500 specialty chemical manufacturer and service company. He has also been an audit manager for Ernst and Young where he was a Certified Public Accountant on the audit staff serving the firm’s clients whose shares are publicly traded. Mr. Peabody received a Bachelor Degree in Business Administration from the University of Michigan.
Dr. Raphael (Rafi) Hofstein joined MaRS Innovation as President and CEO in June, 2009.
Dr. Hofstein received his PhD and Master of Science degrees in Life Sciences and Chemistry from the Weizmann Institute of Science in Rehovot, Israel. His Bachelor of Science degree in Chemistry and Physics was attained from the Hebrew University in Jerusalem. Awards received while completing post-doctoral training and research at the Harvard Medical School in Boston in the Departments of Biological Chemistry and Neurobiology include the Hereditary Disease Foundation Fellowship in 1982-83, and the Chaim Weizmann Postdoctoral Fellowship in 1980-82.
From 1999 to June 2009 Dr. Hofstein held the position of President and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem. He serves as Chair of Hadasit BioHolding Ltd., a holding company for a cluster of companies engaged in drug development and medical diagnostics. Hadasit BioHolding Ltd. has been publicly traded on the Tel Aviv Stock Exchange (TASE) since 2006.
Tami Kfir,CEO, HBL Hadasit Bio Holdings
Ms. Kfir is the CEO of HBL Hadasit Bio Holdings since 2014. Ms. Kfir was a ‘Venture Partner’ at Infinity IP Bank for the last five years and has extensive experience in cross-border deals and provided expertise in the establishment of a technological incubator in Harbin, China. Ms. Kfir is the founder and the CEO of BP&C Consulting Group, which specializes in investment management, commercialization deals and incubators mainly in the field of Life Sciences. Ms. Kfir serves as a board member for a number of private companies and Israeli public companies traded on the TASE. She was the CEO of Knowledge Tree Ventures Inc. and was formerly VP licensing, healthcare at Yissum, the technology transfer company of the Hebrew University of Jerusalem. Previously, she worked as a CFO at Portman Pharmaceutical Industries LTD. Ms. Kfir has extensive experience in license deals, technology collaborations, investments and incubators. Ms. Kfir holds a B.A. in business and economics and M.A. in economics and finance, both from Bar-Ilan University.
Francine Del Ricci
Francine Del Ricci has over twenty five years of experience in the pharmaceutical industry and currently serves at the Vice President of Corporate Alliance Management and Portfolio Governance at Teva Pharmaceuticals. Prior to working for Teva Pharmaceuticals, Francine was the head of Project Leadership at Cephalon and previous to that she worked in both the Pharmaceutical and Consumer Healthcare sectors of Johnson & Johnson. Her experience includes Project and Portfolio Management, Alliance Management, as well as positions in Pharmaceutical Development, Technology Transfer, Manufacturing, and Supply Chain.